Unambiguous assignment of restriction enzyme patterns to six individual serotypes of human rhinovirus was accomplished after amplification of a 380 bp DNA fragment derived from the 5' non-coding region. This was possible even though serotypes 1A and 1B and serotypes 2 and 49 differed only at 10 and 15 positions respectively. The method utilizes the conserved and variable components of this part of the genome and provides the basis for a simple and rapid method for typing of human rhinoviruses.
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Over 100 serotypes of human rhinovirus (HRV), the major causative agent of the common cold, have been described (Stott & Killington, 1972; Hamparian et al., 1987) . Epidemiological determination of the importance of particular serotypes is hampered by the laborious methods employed in serological typing. At present, however, the diagnosis of a rhinovirus and the determination of the serotype can be made only in this way (Cooney et al., 1982; Kellner et al., 1988) .
The nucleotide sequences of the RNA genomes of four HRVs (HRV14, HRV2, HRV89 and HRV 1 B) (Stanway et al., 1984; Callahan et al., 1985; Skern et al., 1985 ; Duechler et al., 1987; Hughes et al., 1988) are available. Analysis of the sequence has revealed the presence of significant stretches of sequence identity in the 5' non-coding regions of these and other picornavirus genomes (Duechler et al., 1987; Hughes et al., 1988) . Specifically for rhinoviruses, identity of the regions between 161 and 181, and between 531 and 553 was found (nucleotide numbering according to HRV2; see Skern et al., 1985) . The sequence variability between these stretches in the four sequenced rhinovirus serotypes provided the basis of a new method of typing rhinoviruses using the polymerase chain reaction (PCR; Saiki et al., 1988) . The applications of PCR are widespread; antenatal diagnosis and determination of the presence of human immunodeficiency disease virus are among its applications (Kogan et al., 1987; Ou et al., 1988) . Primers derived from the conserved regions allowed PCR amplification; the variability enabled identification through restriction enzyme analysis of the amplified cDNAs.
To examine the feasibility of this idea, PCR amplification of the cDNA from various serotypes was carried out. HRVs were obtained by infecting HeLa cells (grown in 150 cm 2 Tflasks) at an m.o.i, of approximately 1. All HRV serotypes analysed were obtained from the ATCC (except for HRV2 which was from Dr D. A. J. Tyrrell at the MRC Common Cold Unit, Salisbury, U.K.) and were plaque-purified before use. The yield was typically 109 p.f.u, in 30 ml medium. After two cycles of freezing and thawing to achieve cell lysis, the medium was cleared of cell debris by a low-speed centrifugation. Virus was concentrated with polyethylene glycol (PEG) and resuspended in 1 ml phosphate-buffered saline. In later experiments, this step was omitted. RNA was obtained by treatment of 0-1 ml of the PEG-concentrated viral suspension or of 0-5 ml of the original suspension with 1 ~o SDS and 10 mM-EDTA. After extraction with phenol/chloroform, 2 ~tg of carrier tRNA was added and the RNA precipitated with ethanol. cDNA was prepared using the entire RNA preparation, 10 pmol of primer 2 (see below) and 10 units of reverse transcriptase (Super RT, Anglian Biotechnology) in 20 ~tl final volume following the instructions given by the supplier. PCR amplification of the cDNAs was then carried out using two primers derived from the regions of identity described above: oligonucleotide primer 1 (sequence 161 to 178) and oligonucleotide primer 2 (complementary to 531 to 544). The amplification reaction was carried out in 50 ~tl total volume with 10 ~tl of the cDNA preparation, 100 pmol each of primers 1 and 2, 0.4 mM each dNTP, 2 units of Thermus aquaticus D N A polymerase (Cetus) in the buffer recommended by Cetus, using the apparatus described (Torgersen et al., 1989) for 30 cycles at settings of 92 °C (2 min), 40 °C (3 min) and 70 °C (3 min). Fig. 1 shows the polyacrylamide gel analysis of an amplification experiment using seven different HRV serotypes; 10 ~tl samples of the reaction mixture were analysed directly on a 6~ polyacrylamide gel (Maniatis et al., 1982) . In each case, a D N A fragment of approximately 380 bp (corresponding to the distance between the two primers) was generated; thus, the primers were able to bind to the cDNAs of HRV1A, HRV49 and HRV70, implying that the sequences are also present in these serotypes. Similar primers have been recently used to demonstrate that amplification of the cDNA of HRV2 isolated from nasal extracts is possible (Gama et al., 1988) .
As no sequence information from HRV1A, HRV49 or HRV70 was available, partial DNA sequence was determined from the amplified fragments derived from HRV1A and HRV49 to examine whether characteristic restriction enzyme sites were present. The dideoxynucleotide sequencing method was used (Sanger et al., 1977) . PCR products were purified by electroelution from polyacrylamide gels and sequenced using primer 1 or 2 and modified T7 polymerase (Pharmacia) according to the supplier's instructions. Computer analysis of D N A sequences was done using the programs of Staden, as modified by Isono (1982) . 241 bp of sequence was obtained for HRV49 and 219 bp for HRV1A. Such analysis showed that the sequence of HRV49 was closely related to that of HRV2 and the sequence of HRV1A to that of HRV1B. The differences between the sequences of HRV2 and HRV49 and between those of HRV1A and HRV1B are shown in Fig. 2(a) and (b) , respectively. A total of 12 base changes and three deletions were observed between HRV2 and HRV49 in the 241 bp sequenced. In the 210 bp analysed for HRV1A and HRV1B, nine base changes and one insertion were observed. These changes resulted in the generation or loss of restriction enzyme sites (e.g. in HRV49 a HindlII site is lost and a DralII site gained with respect to HRV2, as shown in Fig. 2 ) enabling characteristic sites for each serotype to be selected. Restriction enzymes were selected to allow unambiguous identification of the serotypes; Table 1 shows the enzymes chosen together with the fragment sizes. For HRV 1A and HRV49, it was assumed that no further sites for the enzymes in question were present in the regions for Table 1 . The serotypes and enzymes are given above the individual lanes. Abbreviations: Ba, BanlI; Bg, BgllI; Dr, DrallI; Ec, EcoRI; Hn, HinPI; Hd, HindllI; Pv, PvulI; Rs, RsaI; M, markers. The sizes of the markers are indicated in base pairs. which the sequence had not been determined. To simplify the identification of serotypes, amplified fragments from each serotype were restricted with BanlI, and the products analysed on 6~o polyacrylamide gels. The D N A fragments of HRV2, HRV49 and HRV89 possess a site for this enzyme (Fig. 3a) whereas the fragments from HRV1A, HRV1B and HRV14 do not (Fig. 3b) . Thus, the use of this enzyme enables the serotypes selected in this study to be divided into two groups; moreover, the different fragment lengths obtained from HRV2 and HRV89 allowed these serotypes to be identified, as shown in Fig. 3 (a) . The characteristic HindlII site of HRV2 and the RsaI site of HRV89 gave further confirmation. HRV2 and HRV49 could be differentiated using the absence of the HindlII site and the presence of the DralII site in HRV49.
For the serotypes not possessing a BanlI site (Fig. 3b) , HRV14 was identified with the EcoRI site (the digest is partial). HRV1B and HRV1A both have a BgllI site at the same position; the presence of a HinPI site in HRV 1A allowed discrimination between the two serotypes. As only two fragments were obtained with HinPI, the site marked in Fig. 2 must indeed be unique in the amplified fragment. The experiments shown here form the basis of a rapid method of rhinovirus typing. The amplification of seven serotypes, including three of unknown sequence, showed that the conserved regions are present in these serotypes, and implies that these primers will be generally applicable. The presence of restriction sites enabling the discrimination between the closely related serotypes HRV2 and HRV49, HRV1A and HRV1B, suggests that differences in restriction sites alone will be sufficient for identification, even in a fragment that is only 380 bp long. Sequencing of the amplified fragment will therefore not be necessary. Furthermore, the division of the serotypes into groups depending on the presence or absence of a particular site should enable a hierarchical scheme to be devised, again contributing to the ease of diagnosis.
The availability of such a rapid method for the typing of rhinoviruses will allow the identification of serotypes circulating within a population and will thus facilitate epidemiological studies. At present, in order to determine the presence of any given virus, nasal washings are routinely passaged in HeLa cells, a procedure also necessary to obtain suitable quantities for further analysis. The amount of material for an amplification used here is similar to that 'obtained after a single passage; however, it should be feasible to work with the nasal washings themselves as described by Gama et al. (1988) since the 380 bp fragment was generated using dilutions of supernatant estimated to contain one infectious virus particle (data not shown). It is thus probable that the method described here will be more sensitive and informative than the detection of rhinovirus serotypes by hybridization with oligonucleotides derived from the 5' noncoding region .
Further work will be necessary to establish whether clinical isolates can be identified in this manner. Problems may arise owing to the presence of two serotypes or the preferential amplification of one serotype relative to another. Furthermore, it will be important to ascertain whether all isolates of the same serotype have identical restriction patterns; it has been recently shown for poliovirus that considerable variation in this region can occur between isolates of the same serotype (Minor & Dunn, 1988) . The presence of poliovirus itself in clinical isolates may also require examination, as a search of DNA sequence banks revealed that besides rhinoviruses, all strains of poliovirus 1 and 2 and strain 23127 of poliovirus 3 would be amplified. These poliovirus strains can however be detected using characteristic restriction sites. No amplification with coxsackievirus is expected under these conditions.
In conclusion, it has been demonstrated that restriction enzyme analysis in conjunction with DNA amplification technology can be used to identify rhinovirus serotypes, thus providing a useful method for rapid typing. Moreover, it can be envisaged that this procedure might be applicable to other viruses exhibiting a similar arrangement of conserved blocks of sequence between different serotypes.
